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ABSTRACT
Methylation of CpG islands is associated with
transcriptional repression and, in cancer, leads to
the abnormal silencing of tumor suppressor genes.
We have developed a novel technique for detecting
CpG-methylated DNA termed methyl-binding (MB)-
PCR. This technique utilizes a recombinant protein
with high affinity for CpG-methylated DNA that
is coated onto the walls of a PCR vessel and
selectively captures methylated DNA fragments
from a mixture of genomic DNA. The retention and,
hence, the degree of methylation of a specific DNA
fragment (e.g. a CpG island promoter of a specific
gene) is detected in the same tube by gene-
specific PCR. MB-PCR does not require bisulfite
treatment or methylation-sensitive restriction and
provides a quick, simple and extremely sensitive
technique allowing the detection of methylated DNA,
in particular in tumor tissue or tumor cells from
limited samples. Using this novel approach, we
determined the methylation status of several estab-
lished and candidate tumor suppressor genes and
identified the ICSBP gene, encoding the myeloid
and B-cell-specific transcription factor interferon
consensus sequence-binding protein, as a target
for aberrant hypermethylation in acute myeloid
leukemia.
INTRODUCTION
During the past few years it has become increasingly clear
that the formation of tumors is supported not only by genetic
lesions (e.g. mutations or translocations) but also by epigen-
etic changes, including alterations in the methylation status of
DNA (1,2). In mammals, methylation of DNA occurs at spe-
ciﬁc cytosine residues which precede a guanosine residue
(CpG-dinucleotides) and generally correlates with stable tran-
scriptional repression (3–5). The aberrant gain of DNA
methylation (hypermethylation) in neoplastic cells frequently
affects DNA sequences with a relatively high content in
CpG-dinucleotides, the so-called CpG islands. These regions
often contain transcription initiation sites and promoters and
with only few exceptions are generally not methylated in
normal cells (3,4,6–8). It is particularly in tumors that CpG
islands that are normally not methylated can be present in a
hypermethylated form. In many cases, genes affected by
the hypermethylation encode proteins that counteract the
growth of a tumor such as tumor suppressor genes
(1,2,9,10). Reasons for the tumor-speciﬁc hypermethylation
are unknown. Interestingly, certain kinds of tumors seem to
have their own hypermethylation proﬁles (11,12). Promoter-
hypermethylation events may actually provide some of the
most promising markers that can be used to improve cancer
detection and the assessment of cancer risk. Hence, the detec-
tion of CpG-methylated DNA and thus the identiﬁcation of
dysregulated tumor suppressor genes and/or oncogenes is of
outmost clinical interest (2,13,14).
Here, we present a novel, single tube, PCR-based techni-
que that we termed methyl-binding (MB)-PCR, allowing
the sensitive detection of CpG island-speciﬁc methylation.
This novel method avoids the manipulation of DNA by
methylation-sensitive restriction endonucleases or bisulﬁte
treatment and relies on the ability of a recombinant, bivalent,
methyl-CpG-binding polypeptide to speciﬁcally bind CpG-
methylated DNA fragments. The single tube assay involves
the fractionated binding of restricted genomic DNA by the
recombinant methyl-CpG-binding polypeptide immobilized
on the walls of a PCR vessel and the subsequent detection
of bound DNA by PCR in the same tube. Given the enormous
ampliﬁcation capability and speciﬁcity of PCR, MB-PCR can
reliably detect the methylation degree of a speciﬁc genomic
DNA fragment from <30 cells.
Using the described technique, we determined the methyla-
tion status of several established (ESR1; CDKN2B) and
candidate tumor suppressor genes (ICSBP, ETV3, DDX20)
in leukemia cell lines, normal cells and blasts from 35 patients
with newly diagnosed, untreated acute myeloid leukemia
(AML). We conﬁrm earlier studies showing the frequent
methylation of the estrogen receptor (ESR1) as well as the
CDKN2B (also known as p15
INK4b) CpG island promoter
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doi:10.1093/nar/gkl437(15–17). We also identify ICSBP as a target for aberrant
promoter methylation in a subset of AML patients.
MATERIALS AND METHODS
Cells
Peripheral blood mononuclear cells (MNC) were separated
by leukapheresis of healthy donors, followed by density gra-
dient centrifugation over Ficoll/Hypaque. Monocytes were
isolated from MNC by countercurrent centrifugal elutriation
in a J6M-E centrifuge (Beckman, Mu ¨nchen, Germany) as
described previously (18). Drosophila S2 cells were obtained
from ATCC and cultured in Insect-Xpress medium (Bio
Whittaker) containing 10% fetal calf serum (FCS; PAA) in
an incubator at 21 C. The human myeloid leukemia cell
lines THP-1, NB-4, KG-1, K562, HL-60 and U937 were
grown in RPMI 1640 medium supplemented with 10%
FCS. The human myeloid leukemia cell line Mono Mac 6
was grown in RPMI 1640 medium plus 10% FCS and 1%
OPI media supplement (Sigma). The human myeloid leuk-
emia cell line MUTZ-3 was maintained in aMEM plus
20% FCS and 10 ng/ml stem cell factor. For DNA-
demethylation, U937 cells were treated with the indicated
amounts of Decitabine (2-deoxy-50-azacytidine; Sigma) for
several days.
Patient samples
Fresh peripheral blood samples and bone marrow specimens
from 35 patients with newly diagnosed and untreated de novo
or secondary AML were used for the study. All patients
were treated according to the protocol AMLCG-2000 of the
German AML Cooperative Group. The study was approved
by the Institutional Ethics Committee, and written informed
consent was obtained from each patient before entering the
study.
Recombinant expression of the methyl-binding
polypeptide MBD-Fc
A detailed description of the design and generation of
the MBD-Fc protein will be given elsewhere (19). In brief,
a cDNA corresponding to the methyl-CpG-binding domain
of human MBD2 (amino acids 144–230) was PCR-ampliﬁed,
fused to the Fc-tail of human IgG1, and subcloned into the
inducible expression vector pMTBiP/V5-His (Invitrogen).
The resulting vector was stably transfected into Drosophila
S2 cells using Effectene transfection reagent (Qiagen) and
hygromycin selection. For large-scale protein production,
1–5 · 10
8 cells were cultured in 100–200 ml Insect-Xpress
medium without FCS in 2000 ml roller bottles for 2 days
before the addition of 0.5 mM CuSO4. Culture medium was
harvested every 4–7 days and cells were replated in medium
plus CuSO4 for continued protein production. Cell culture
supernatants were pooled and puriﬁed using a protein
A–Sepharose (Amersham) column. The puriﬁed protein
(200–700 mg/ml) was dialyzed against TBS and 0.6%
gelatine/0.02% NaN3 was added as preservative.
DNA preparation
Genomic DNA from various cellular sources was prepared
using the Blood and Cell Culture DNA Midi Kit from
Qiagen. Quality of the genomic DNA preparation was
controlled by agarose gel electrophoresis and DNA concen-
tration was determined by UV spectrophotometry. Genomic
DNA was digested with MseI (NEB) and quantiﬁed using
PicoGreen dsDNA Quantiﬁcation Reagent (Molecular
Probes). Where indicated, DNA was in vitro methylated
using SssI methylase (NEB).
Preparation of PCR tubes for MB-PCR
MBD-Fc-coated PCR tubes were prepared using heat stable
TopYield  Strips (Nunc). Recombinant MBD-Fc protein
(50 ml, diluted at 15 mg/ml in 10 mM Tris–HCl, pH 7.5)
were added to each tube and incubated overnight at 4 C.
Tubes were washed three times with 200 ml TBS (20 mM
Tris, pH 7.5, containing 170 mM NaCl) and blocked for
3 h with 100 ml blocking solution [10 mM Tris, pH 7.5,
containing 170 mM NaCl, 5% skim milk powder, 5 mM
EDTA and 1 mg/ml of each poly(dI–dC), poly(dA–dT) and
poly(dC–dG) (Amersham)]. Tubes were washed two times
with 200 ml TBST (TBS containing 0.05% Tween-20) and
once with binding buffer (20 mM Tris, pH 7.5, containing
400 mM NaCl, 2 mM MgCl2, 0.5 mM EDTA and 0.05%
Tween-20).
Binding of methylated DNA (M-reaction)
Binding buffer (50 ml) (20 mM Tris, pH 7.5, containing
400 mM NaCl, 2 mM MgCl2, 0.5 mM EDTA and 0.1%
Tween-20) was added to each coated, blocked and washed
tube and 2 ml digested DNA (5 ng/ml) was added to every
second tube (M-reaction). The salt concentration in the bind-
ing buffer was initially determined in pilot experiments to
allow the efﬁcient binding of highly methylated but not
unmethylated CpG island fragments. The salt concentration
determines the ‘cut-off’ and may be adjusted for individual
DNA fragments. Tubes were incubated on a shaker at room
temperature for 40 min, washed two times with 200 ml bind-
ing buffer and once with 200 ml of 10 mM Tris–HCl, pH 8.0.
Detection of methylated DNA fragments
PCR was carried out directly in the treated and washed
TopYield  Strips. The PCR mixture (50 ml/well) included
10 pmol of each gene-speciﬁc primer (synthesized by
Metabion). Primer sequences were P15 S (50-GGC TCA
GCT TCA TTA CCC TCC-30), P15 AS (50-AAA GCC
CGG AGC TAA CGA C-30), ESR1 S (50-GAC TGC ACT
TGC TCC CGT C-30), ESR1 AS (50-AAG AGC ACA GCC
CGA GGT TAG-30), ICSBP S (50-CGG AAT TCC TGG
GAA AGC C-30), ICSBP AS (50-TTC CGA GAA ATC
ACT TTC CCG-30), METS S (50-AAT TGC GTC TGA
AGT CTG CGG-30), METS AS (50-TCC CAC ACA ACA
GAG AGG CG-30), DP103 S (50-GCT GTT AGT CCA
GTT CCA GGT TCC-30), DP103 AS (50-GTG CAA CCA
CAT TTA TCT CCG G-30), Chr6-S (50-GAA ACC CTC
ACC CAG GAG ATA CAC-30), Chr6-AS (50-TGC AGT
GGG ACT TTA TTC CAT AGA AGA G-30), Chr9-S (50-
GTG TCC ACA TCT CTT CTG GGT AAC TC-30) and Chr6-
AS (50- AGT AAG CTC CTT TCC CTA AGC CA-30). After
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was added to every other well, that was not incubated previ-
ously with DNA fragments (P-reaction). PCR was performed
on a MJResearch engine with the following cycling condi-
tions: 95 C for 3 min (denaturation), 94 C for 20 s, 60 C
for 20 s and 72 C for 70 s (36 cycles) and 72 C for 5 min
(ﬁnal extension). Initial pilot experiments showed that the
reaction was still in the linear phase of ampliﬁcation using
the above conditions (Figure 2B). The MB-PCR products
(20 ml) were analyzed using 3% agarose gel electrophoresis
and the ethidium bromide stained gels were scanned using
a Typhoon 9200 Imager (Amersham/Pharmacia).
Sodium bisulfite sequencing
Modiﬁcation of DNA with sodium bisulﬁte (20) was per-
formed as described previously (21). Bisulﬁte-treated DNA
was ampliﬁed in a nested PCR using the primers icsbp-out
S( 5 0-GGG GTA GTT AGT TTT TGG TTG-30) and icsbp-
out AS (50-ATA AAT AAT TCC ACC CCC AC-30) for the
ﬁrst and icsbp-in S (50-TTG TGG ATT TTG ATT AAT
GGG-30) and icsbp-in AS (50-CCR CCC ACT ATA CCT
ACC TAC C-30) for the second round of ampliﬁcation.
PCR products were cloned using TOPO-TA Cloning Kit
(Invitrogen) and several independent clones were sequenced.
RNA-preparation, real-time PCR
Total RNA was isolated from different cell lines by the
guanidine thiocyanate/acid phenol method (22). RNA
(2 mg) was reverse transcribed using Superscript II MMLV-
RT (Invitrogen). Real-time PCR was performed on a Light-
Cycler (Roche) using the Quantitect kit (Qiagen) according
to the manufacturer’s instructions. Primers used were
ICSBP, sense 50-CGT GGT GTG CAA AGG CAG-30, anti-
sense 50-CTG TTA TAG AAC TGC TGC AGC TCT C-30;
and ACTB, sense 50-TGA CGG GGT TCA CCC ACA CTG
TGC CCA TCT A-30, antisense 50-CTA GAA GCA TTT
GTG GTG GAC GAT GGA GGG-30. Cycling parameters
were denaturation 95 C, 15 min, ampliﬁcation 95 C, 15 s,
57 C, 20 s, 72 C, 25 s, for 50 cycles. The product size was
initially controlled by agarose gel electrophoresis and melting
curves were analyzed to control for speciﬁcity of the PCRs.
ICSBP data were normalized for expression of the ACTB
gene. The relative units were calculated from a standard
curve plotting three different concentrations of log dilutions
against the PCR cycle number (CP) at which the measured
ﬂuorescence intensity reached a ﬁxed value. The ampliﬁ-
cation efﬁciency E was calculated from the slope of the
standard curve by the formula E ¼ 10
 1/slope. EICSBP ranged
from 1.87 to 1.98 and EACTB ranged from 1.76 to 1.84.
For each, sample data of three independent analyses were
averaged.
RESULTS
Outline of the MB-PCR technique
We reasoned that a methyl-CpG DNA-binding polypeptide
covalently coupled to the vessel walls of a PCR tube might
allow the binding and detection of CpG-methylated DNA
in a manner comparable to the standard ELISA techniques.
Initial pilot experiments led to the establishment of a proce-
dure, termed MB-PCR, that could reliably detect CpG-
methylated DNA fragments. The basic steps of this novel
technique are outlined in Figure 1. In the ﬁrst step, a protein
with high afﬁnity for CpG-methylated DNA is coated onto
the walls of a PCR-cycler compatible reaction tube and
used to selectively capture strongly methylated DNA frag-
ments from a genomic DNA mixture. The retention of a
speciﬁc DNA fragment (e.g. a CpG island promoter of a spe-
ciﬁc gene) is detected in the same tube using PCR (the
M-reaction). The degree of methylation may be estimated
relative to a PCR of the genomic input DNA (the P-reaction).
Figure 1. Outline of MB-PCR. The major steps of the MB-PCR procedure are
illustrated. MB-PCR comprises two separate reactions, the control-PCR
(P-reaction) which amplifies a candidate locus directly from a genomic
template, and the MB-PCR which amplifies the candidate locus from the
template DNA that was bound previously by the methyl-CpG-binding
polypeptide in the reaction vessel (M-reaction). In the first step, the inner
walls of both reaction vessels are coated with a methyl-binding polypeptide
and subsequently saturated using blocking reagents (step 2). The template
DNA (genomic DNA restricted with MseI or similar enzymes) is then added
to one tube (M-reaction) and allowed to bind (step 3). In the last step, the PCR
mixture is added directly into both tubes and 50% of template DNA used
previously for the M-reaction is added to the P-reaction. After gene-specific
PCR, products may be analyzed, e.g. by agarose gel electrophoresis.
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CpG-methylated DNA, we used a fusion protein comprising
the methyl-CpG-binding domain (MBD) of human MBD2,
a ﬂexible linker polypeptide and the Fc portion of human
IgG1. MBD2 was chosen, because previous binding studies
suggested that its methyl-binding domain shows a high
afﬁnity to CpG-methylated DNA when compared to other
mammalian MBD proteins. The bivalent structure of the
antibody-like MBD-Fc protein likely further increases its
afﬁnity and avidity towards CpG-methylated DNA. Design,
production and properties of the MBD-Fc protein will be
described elsewhere (19). Brieﬂy, its afﬁnity to a given
DNA fragment depends on the following variables: (i) the
amount of salt in the reaction or washing buffer (low salt
requires little CpG methylation for binding, high salt requires
more CpG methylation for binding); (ii) the number of
methylated CpG-dinucleotides; and (iii) the density of the
MBD-Fc protein on the interaction surface.
The binding reaction and two washing steps are performed
in a stringent high salt buffer (400 mM NaCl) assuring that
fragments with little or no methylation are washed off. In
contrast to most previous methods, detection of CpG
methylation by MB-PCR therefore largely depends on the
degree/number of methylated cytosine residues in a given
DNA fragment.
We explored the MB-PCR method by analyzing the degree
of CpG methylation of single CpG island promoters that were
shown previously to be frequently methylated in leukemia
cells, namely the human CDKN2B gene (also known as
p15
INK4b) and the human estrogen receptor 1 (ESR1) gene.
In addition to the well-established tumor markers we selected
three additional genes with CpG island promoters that could
potentially act as tumor suppressor genes: the human
interferon consensus-binding protein (ICSBP) gene, the
human Ets variant 3 gene (ETV3) and the human DEAD
box polypeptide 20 gene (DDX20). ICSBP, a transcription
factor of the interferon (IFN) regulatory factor family
(IRF), is frequently down-regulated in human myeloid leuk-
emia (23) and ICSBP-deﬁcient mice display hematological
alterations similar to chronic myelogenous leukemia (CML)
in humans (24), suggesting a tumor suppressor function for
ICSBP in hemopoietic cells. In mice, the Ets repressor
ETV3 (also known as METS or PE1) and its co-repressor
DDX20 (also known as DP103) were shown to link terminal
monocytic differentiation to cell-cycle arrest (25), which may
also indicate a possible tumor suppressor role. As negative
controls for the binding and washing procedure, we also
designed two sets of primers that detect CpG-free genomic
MseI fragments on chromosomes 6 and 9.
To allow for a semi-quantitative analysis of the genomic
PCR, we initially tested a series of DNA dilutions at various
cycle numbers. As shown in Figure 2B using 36 cycles our
PCR approach was able to detect a range of 5 ng down to
at least 250 pg, suggesting that ethidium bromide stained
PCR fragments could be semi-quantitatively analyzed under
these conditions. As a validation of our MB-PCR approach,
genomic DNA from normal cells was either left untreated
or methylated in vitro using SssI, digested with MseI and
subjected to MB-PCR. Genomic DNA was digested with
MseI because this enzyme is methylation insensitive and
cuts DNA into small fragments while leaving CpG islands
relatively intact (26). Locations of the detected MseI
fragments relative to the ﬁrst exon of their respective genes
as well as positions of gene-speciﬁc primers used for
Figure 2. MB-PCR detects methylation of CpG island promoters. (A) Schematic presentation of the detected MseI-fragments (indicated as gray boxes) of ESR1,
CDKN2B (p15
INK4b), ICSBP, ETV3 and DDX20. The position of CpG-dinucleotides, MseI-restriction sites, transcription start site, first exon and relative position
of primers are marked. (B) P-reaction for ICSBP using a serial dilution of MseI-digested genomic DNA. (C) Representative MB-PCR results of normal
(unmethylated) and in vitro methylated genomic DNA for the indicated promoters and CpG-free regions. The P-reaction directly amplifies the genomic DNA,
whereas the M-reaction only amplifies CpG-methylated DNA fragments.
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containing regions include the putative proximal promoter
regions. As shown in Figure 2C, the M-reactions of all ﬁve
gene loci were negative when normal DNA was used, indic-
ating that these genomic regions are, as expected, free of
methylation in normal blood cells. However, each locus
was ampliﬁed in the corresponding M-reaction when the
same DNA was in vitro methylated using SssI-methylase
before it was subjected to MB-PCR. The CpG-free genomic
regions were not ampliﬁed in untreated and SssI-treated
DNA, suggesting that the ampliﬁcation of a genomic DNA
fragment requires the presence of DNA methylation and
that no unmethylated DNA is retained after washing.
Hence, MB-PCR is able to discriminate the methylated and
unmethylated state at these loci.
Methylation status of specific CpG island promoters
in tumor cell lines analyzed by MB-PCR
To test whether MB-PCR is able to detect the methylation
status of the above loci in biological samples, we analyzed
several leukemia cell lines. Routinely, a total of 10 ng of
restricted DNA was used for the M-reaction and 5 ng of
the same digested genomic DNA was used for the P-reaction.
The result of a representative MB-PCR experiment from
eight different leukemia cell lines is shown in Figure 3A.
The ESR1 promoter was ampliﬁed to varying degrees in
the M-reaction of all eight samples, which is in line with
previous reports demonstrating its aberrant methylation in
>80% of human hemopoietic tumors. The P-reaction for the
CDKN2B promoter failed completely in three cell lines
(THP-1, NB-4 and K562) suggesting mutations or deletions
on both alleles, which has been demonstrated previously in
the cases of NB-4 (16) and K562 (27). The two cell lines
KG-1 and MUTZ-3 showed a positive M-reaction for the
CDKN2B promoter, whereas three cell lines (U937,
MonoMac6 and HL-60) were negative. The observed results
were in good concordance with previously published
methylation analyses of ESR1 (28) and CDKN2B promoters
(15,16,27). In some cases, P-reactions were weaker in com-
parison with other cell types, suggesting the loss or mutation
of one allele (e.g. ESR1 in U937 cells). Interestingly, the
ICSBP promoter was also ampliﬁed in M-reactions of six
cell lines, whereas no signiﬁcant methylation was detected
at the promoters of ETV3 and DDX20 genes. The two negat-
ive control fragments on chromosomes 6 and 9 were positive
in the P-reaction but also negative in the M-reaction (data not
shown).
Since aberrant CpG methylation at the ICSBP locus has not
been described previously, the degree and effect of ICSBP
promoter methylation was analyzed to further validate the
experimental potential of MB-PCR. To determine how
MB-PCR results correlate with the exact pattern of CpG
methylation at the ICSBP promoter in individual cell lines,
we analyzed ICSBP promoter methylation by bisulﬁte
sequencing. The results shown in Figure 3B indicate that
the degree of promoter methylation corresponds with results
obtained by MB-PCR. Strong ampliﬁcation signals (com-
parable with the corresponding P-reaction) as seen in KG-1,
U937, MUTZ-3, HL-60 and K562 cell lines, appear to indic-
ate a high degree, whereas weaker signals (as observed
for NB-4 cells) indicate a lesser degree of methylation. In
the absence of DNA methylation (THP-1 and MonoMac6
cells) the MB-PCR is negative. As shown in Figure 4A,
mRNA expression levels analyzed by LightCycler real-
time PCR inversely correlated with methylation degree
as determined by MB-PCR and bisulﬁte sequencing. Treat-
ment of U937 cells, which show a high degree of ICSBP
promoter methylation with the demethylating agent
Decitabine (5-Aza-20Deoxycytidine) led to a marked,
dose- and time-dependent induction of ICSBP mRNA exp-
ression (Figure 4B), indicating that the methylation-
induced repression of ICSBP transcription is reversible in
these cells.
Figure 3. Detecting CpG methylation in leukemia cell lines by MB-PCR. (A) Shown are representative MB-PCR results of eight different leukemia cell lines for
the indicated promoters. (B) Genomic DNA from the same cell lines was analyzed by bisulfite sequencing. The indicated region of the ICSBP gene was amplified
and cloned. Several independent inserts were sequenced and results are presented schematically. Squares mark the position of CpG-dinucleotides (open,
unmethylated; closed, methylated).
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Samples derived from tumors may contain signiﬁcant num-
bers of normal cells, that would be expected to be unmethyl-
ated at most CpG islands. To test how linear the detection of
CpG methylation is with respect to cell purity, MB-PCR was
performed using mixtures of DNA from normal blood cells
(freshly isolated blood monocytes) and a leukemia cell line
KG-1 showing high levels of CpG island methylation at the
promoters investigated in this study. As shown in
Figure 5A, the ICSBP promoter fragment was only detected
in samples containing KG-1 DNA and the signal gradually
increased with the proportion of methylated DNA in the
sample. Similar results were obtained for ESR1 and
CDKN2B loci (data not shown).
To test the sensitivity of our approach, we performed
MB-PCR experiments using decreasing amounts of DNA.
Dilutions of genomic DNA from three different cell lines
(U937, NB-4 and THP-1) were subjected to MB-PCR. To
account for the reduced amount of template DNA in the
PCRs, the cycle number was increased proportionally. As
shown in Figure 5B, comparable results were obtained
using either 10 ng, 2.5 ng, 625 pg or even 160 pg of digested
genomic DNA, suggesting that MB-PCR is able to detect
the methylation status of a single promoter in DNA derived
from as few as 30 cells.
Detecting methylation of CpG island promoters
in primary tumor cells
DNA was prepared from blood monocytes of several healthy
persons (n ¼ 4) and leukemic blasts of patients with previ-
ously untreated AML (n ¼ 35), digested with MseI, and sub-
jected to MB-PCR. Figure 6 shows representative ICSBP
MB-PCR and corresponding bisulﬁte sequencing results for
nine AML patients and one normal individual. In general,
the intensity of the band observed in the M-reaction (as com-
pared with the corresponding P-reaction) showed good cor-
relation with the mean density of methylation in the sample.
Out of 35 AML patients tested, 7 patients (20%) showed
positive MB-PCR results for ICSBP, 21 patients (60%) for
ESR1 and 25 patients (71%) for CDKN2B (data not shown).
The frequencies for ESR1 and CDKN2B methylation
observed concur with those described in previous studies
(16,28). ICSBP methylation apparently only affects a sub-
group of patients. Twelve patients were tested for methyla-
tion of ETV3 and DDX20 genes and, as observed for the
leukemia cell lines, no signiﬁcant methylation was detected
in any of the samples.
Figure 4. Methylation of the ICSBP promoter inversely correlates with
ICSBP expression in leukemia cell lines. (A) Transcription levels of ICSBP
were determined by LightCycler real-time PCR relative to the housekeeping
gene ACTB.( B) U937 cells, treated with Decitabine (DAC) for the indicated
time periods were analyzed for ICSBP expression. Results were normalized to
ACTB expression. Data represent mean values ± SD of two independent
LightCycler analyses.
Figure 5. Sensitivity of MB-PCR. (A) MB-PCRs for the ICSBP promoter from mixtures of DNA from a healthy donor (N, unmethylated) and DNA from the cell
line KG-1 (methylated). The relative contribution of each DNA is indicated in the table on the right. (B) DNA samples from three cell lines were subjected to
MB-PCR using 10 ng and down to 160 pg of DNA for the M-reaction. The number of amplification cycles (given in parentheses) was adjusted to the amount
of DNA.
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We have developed a novel one tube assay, termed MB-PCR,
to detect genomic DNA fragments according to their level of
CpG methylation. The novel technique requires little amounts
of DNA and allows the rapid screening of multiple loci.
MB-PCR is particularly useful to screen for methylation
levels of candidate genes in tumor tissue or tumor cells as
exempliﬁed for acute myeloid leukemia in this report. It
may, however, also be useful to detect changes in DNA
methylation in other situations, including normal cellular
differentiation and aging.
Comparison with existing methods
At present, mainly two technical approaches are used to
detect the level of CpG methylation of known candidate
gene loci: methylation-sensitive restriction or bisulﬁte
treatment of DNA (29).
Isoschizomers of bacterial restriction endonucleases with
different sensitivities for 5-methylcytosine can be used
to determine the methylation status of speciﬁc CpG-
dinucleotides (29). The use of methylation-sensitive restric-
tion enzymes, however, has several limitations. Apart from
the fact that incomplete restriction digests may complicate
the analysis, the greatest disadvantage is that methylation-
sensitive restriction merely informs on the methylation status
of the cytosine residues which are recognized by the
methylation-sensitive restriction enzymes used.
A global picture of the methylation pattern in a candidate
gene locus may be obtained by bisulﬁte sequencing as
originally described by Frommer et al. (20). The treatment
of double-stranded genomic DNA with sodium bisulﬁte
leads to the deamination of unmethylated cytosine residues
(but not 5-methyl cytosine) into uracil residues. DNA
treated with bisulﬁte can be used directly in PCR in which
uracil residues (previously unmethylated cytosine) and
thymidine residues are ampliﬁed as thymidine and only
5-methylcytosine residues are ampliﬁed as cytosine residues
(20). Depending on the application, the primers used for
the PCR differentiate between methylated and unmethy-
lated sequences or amplify fragments independently of the
methylation status (29). PCR fragments which have been
ampliﬁed using non-discriminating primers can, for instance,
be sequenced directly to determine the position of methylated
and unmethylated CpGs. Other methodical approaches
that allow high-throughput analyses utilize the differences
in sequence for the speciﬁc ampliﬁcation of methylated and
unmethylated sequences by discriminating primers or probes
(e.g. methylation-speciﬁc PCR, MethyLight) (29). In contrast
to the methylation-sensitive restriction enzymes, the DNA
treated with bisulﬁte can potentially provide information on
the methylation status of several CpG residues in an ampliﬁed
genomic fragment. The detection of CpG methylation by
using discriminating primers or probes, however, is limited
to the methylation status of single (or few) cytosine residues.
Hence, the information provided by all currently known
assays that are suitable for high-throughput methylation
analysis of single gene loci is limited to one or only a few
CpG residues within the gene of interest.
Rather than analyzing single CpG residues, MB-PCR ana-
lyses target DNA fragments according to their methylation
degree. The information provided by MB-PCR will be
at least as relevant as that obtained with other existing PCR
techniques—the methylation density of a proximal promoter
may actually correlate better with the transcriptional status of
a gene than the methylation status of a single CpG residue
within the region. We believe that the high methyl-CpG
afﬁnity of MBD2 combined with the bivalent, antibody-like
structure of the recombinant MBD-Fc protein greatly
increases its binding capacity, enabling the efﬁcient retention
of a DNA fragment on the basis of its degree of methylation.
A comparable approach discriminating DNA fragments on
the basis of their methylation density was developed in the
laboratory of A. Bird already 10 years ago (26). A recombi-
nant MeCP2 protein bound to a matrix was used in this and a
number of recent studies for binding and enriching highly
methylated DNA through afﬁnity chromatography (26).
Although we have not tested recombinant MeCP2, it is
possible that it may also work as methyl-binding polypeptide
in MB-PCR.
The company Panomics introduced recently a commer-
cially available kit that differentiates promoters with methyl-
ated groups from unmethylated promoters. In principle, the
company’s method consists of a spin column afﬁnity puriﬁca-
tion using MeCP2. This method also appears to be rapid,
Figure 6. Detection of aberrant CpG methylation in primary AML blasts.
Two independent MB-PCRs (independent restriction digest and preparation
of MBD-Fc) for the ICSBP promoter of one representative healthy donor (N)
and nine AML patients are shown together with corresponding sequencing
results. (Results of bisulfite sequencing are presented as described in
Figure 3.)
PAGE 7 OF 9 Nucleic Acids Research, 2006, Vol. 34, No. 11 e82however, it requires a relatively large amount of starting
material. It is not clear, to which extent the information can
be quantiﬁed or whether the amount of isolated fragments
correlates with the degree of promoter methylation. A recent
report by Klose et al. (30) clearly demonstrated that MeCP2
requires an A/T run adjacent to the methylated CpG dinuc-
leotide for efﬁcient DNA binding, suggesting that all methods
based on MeCP2-afﬁnity chromatography, including the
Panomics kit, will be biased towards certain CpG motifs.
Therefore, it is not clear, whether MeCP2 will be able to
detect every methylated CpG island fragment. No binding
requirements or preferences of MBD2 were detected in this
and previous studies (30). Owing to its binding properties,
MeCP2 may be better suited to detect non-CpG island pro-
moters with a lower CpG-density, e.g. CD14, IFNg or IL-4
Promoters (as demonstrated in the user manual of the com-
mercially available kit).
Technical considerations
An important aspect of MB-PCR is the fragmentation of
the genomic DNA. We have used the restriction enzyme
MseI (T/TAA) in our study; however, other methylation-
insensitive restriction enzymes such as Csp6I (G/TAC) or
Tsp509I (/AATT) may also be used (either alone or in
combination) to achieve an appropriate fragmentation of
the target gene. Most informative (with respect to the
effects on transcription) and clearest results (in terms of
noise and background) are obtained when a target gene
fragment contains only the proximal promoter within the
CpG island. In addition to enzyme restriction, DNA
fragmentation may also be achieved by mechanical means,
e.g. ultra-sonication.
As demonstrated, our current approach allowed the distinc-
tion between strong (>30–40% methylation), intermediate
methylation levels (>10%) or no methylation. Owing to the
limitations of standard PCR, a more detailed grading is tech-
nically difﬁcult. In most cases, however, standard MB-PCR
will be sufﬁciently informative to detect aberrant methylation
in a tumor sample. A standardization of individual experi-
ments may be achieved by using a series of mixtures of
methylated and unmethylated DNA as a standard curve for
each experiment. As a control for the completeness of restric-
tion digestion as well as the washing procedure, a DNA frag-
ment is ampliﬁed that contains no CpG residues and therefore
should not be retained and ampliﬁed. Although we have not
yet tested, it is conceivable that MB-PCR may also be run as
a real-time PCR application, which may allow the quantiﬁca-
tion of ampliﬁed products and a better correlation with
methylation levels in a sample.
Since the surface area of the PCR tube and hence its
binding capacity for the recombinant methyl-DNA-binding
polypeptide is limited, it is important to avoid the use of
an excess amount of genomic DNA for the assay. We
found that MB-PCR produces consistent results using
160 pg to 10 ng of restricted genomic DNA. The little amount
of DNA required for MB-PCR is actually a great advantage
of this technique, allowing the methylation analysis of can-
didate genes from very limited cell numbers which may
include biopsy samples or cells collected by laser-mediated
microdissection.
Screening for aberrant CpG methylation
To test the usefulness of MB-PCR for methylation analysis,
we initially analyzed CpG island promoters that were
known to us or described in the literature to be methylated
or unmethylated in particular cell lines, including the pro-
moters of CDKN2B (p15
INK4b) and ESR1 genes. Since initial
results obtained by MB-PCR from several leukemia cell lines
corresponded with previously published observations, we
selected a number of novel putative candidate genes
(ICSBP, ETV3 and DDX20) for further analyses that are
involved in cell-cycle arrest or cellular differentiation and
represented good candidates as tumor suppressor genes.
Using MB-PCR we show that the CpG island promoter of
ICSBP is methylated in many leukemia cell lines and a subset
of patients with AML. MB-PCR results were independently
conﬁrmed by bisulﬁte sequencing and methylation of the
promoter correlated with the absence or down-regulation of
ICSBP transcription in the leukemia cell lines. Our data
suggest that epigenetic silencing may contribute signiﬁcantly
to the observed down-regulation of ICSBP in human myeloid
leukemia. The CpG island promoters of ETV3 and DDX20
were not methylated in any of the samples tested so far.
It will be interesting to analyze the methylation status
of these genes, especially ICSBP, in other malignancies,
e.g. CML or non-myeloid malignancies.
In summary, our report describes a rapid and sensitive pro-
cedure for detecting methylated DNA target sequences from
limited sample material. MB-PCR will be particularly useful
in screening methylation levels of candidate genes not only in
tumor tissue but also in tumor cells. Our study also suggests
that the promoter of ICSBP is hypermethylated in a subgroup
of patients with myeloid leukemia, which may serve as a
molecular marker for disease.
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